BIOTRICITY INC - BTCY STOCK NEWS

Biotricity (NASDAQ:BTCY) reported strong strategic initiatives and growth opportunities in its recent shareholder update. The company has expanded its national sales force to cover 27 states, enhancing demonstrations of its cardiac devices. The FDA cleared its Biotres cardiac monitoring device, expanding its total addressable market (TAM) from $1B to $25B. Biotricity achieved a significant 93% YOY revenue growth to $1.93 million in Q3 2021 and raised $12 million in non-dilutive debt financing. As COVID-19 recedes, the company anticipates increased sales opportunities in 2022.

Biotricity (NASDAQ:BTCY) announced pre-order sales of its FDA-cleared wireless wearable device, Biotres, designed for early detection of cardiac arrhythmias. Official commercial sales will launch in April 2022, following strong pre-order demand from physicians and individual users. Biotres, a three-lead device, enhances ECG monitoring efficiency compared to traditional Holter monitors, positioning the company to tap into a $5.7 billion market. Biotricity plans to expand its product line throughout 2022, aiming to increase revenue and customer reach.

Biotricity, Inc. (NASDAQ:BTCY) announced its participation in the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, California. This follows a strong fiscal third quarter, reporting a 93% year-over-year revenue growth and its highest cash position. The company is now taking preorders for Biotres, a new FDA-cleared wireless cardiac monitoring device aimed at the $5.7 billion market for cardiac arrhythmia monitoring. The device enhances long-term ECG data collection, expected to ship starting April 1, 2022.

Biotricity (NASDAQ:BTCY) has announced the commencement of pre-orders for its new Biotres device, a three-lead ECG monitoring system aimed at early detection of cardiac arrhythmias. Following recent FDA clearance, pre-orders started on February 23, 2022, with shipping scheduled for April 1, 2022. The Biotres device aims to disrupt the existing cardiac monitoring market, valued at approximately $5.7 billion, by providing continuous ECG data and remote uploading capabilities, enhancing diagnostic speed and efficiency.

Biotricity (BTCY) reported Q3 FY22 financial results with a remarkable 93% year-over-year revenue increase to $1.93 million, outpacing the 40% increase in SG&A. The company's cash position reached a historic $16.8 million. Despite a net loss of $7.34 million due to one-time expenses, adjusted loss is $6.0 million. Biotricity anticipates continued triple-digit revenue growth for the full year, fueled by the launch of innovative products like Bioheart and the FDA-cleared Biotres, expanding its addressable market significantly.

SWK Holdings Corporation (Nasdaq: SWKH) updated its portfolio performance for the second half of 2021, highlighting new financings including $10 million to MolecuLight and $12 million to Biotricity (NASDAQ: BTCY). CEO Winston Black noted that 2022 aims to restore deal origination to historical levels. Enteris BioPharma's partnership with Cara Therapeutics is advancing with a $5 million milestone payment. Additionally, Biolase (NASDAQ: BVS) anticipates a 44-47% revenue increase for the fourth quarter. SWK focuses on providing flexible financing solutions to small and mid-sized life science companies.

Biotricity (NASDAQ:BTCY) is set to release its third quarter fiscal 2022 financial results on February 14, 2022, after the market closes. Management will discuss the results during a conference call on February 15, 2022, at 4:15 p.m. EST. The company anticipates 2022 as a breakout year, emphasizing the commercial launch of Bioheart and FDA clearance for Biotres. Biotricity focuses on remote health monitoring and chronic care management, aiming to enhance preventive and personal care for patients.

Biotricity, Inc. (NASDAQ:BTCY) has received 510(k) clearance from the FDA for its Biotres cardiac monitoring device, targeting the $2 billion holter market.

This innovative device allows continuous 3-channel ECG recordings for lower-risk patients, with features including a rechargeable battery, wireless connectivity, and user-friendly design. Biotres expands Biotricity's Total Addressable Market from $1 billion to $5.7 billion, with sales expected to begin on April 1, 2022. The CEO emphasizes its potential to enhance cardiac care and reduce costs.